Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | SVP, Technical Operations | August 12, 2019 | August 14, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 12, 2019 · Filed August 14, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 16,418 |
Reported balance
After 2019-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-12 · Sale · Disposed 4,371 · Balance 16,418 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.4015 to $137.4322, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F2: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019. |
| Ordinary SharesSEC Table I · non-derivative | Indirectby Trust | 106 |
Reported balance
Holding disclosure · report date 2019-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 106 F3: Represents ordinary shares purchased by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme on March 15, 2019 in a transaction exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.4015 to $137.4322, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019.
F3: Represents ordinary shares purchased by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme on March 15, 2019 in a transaction exempt under Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2019 Filed Aug 14, 2019 21:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,371 | $137.40 | $600,588.51 |
DisclosureSEC source: 0001765581-19-000086 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,418 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.4015 to $137.4322, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. F2 · balance_after: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 00:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 589 | $135.41 | $79,756.49 |
DisclosureSEC source: 0001765581-19-000043 · edgardoc.xml · nonDerivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,649 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 00:18 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 471 | $135.41 | $63,778.11 |
DisclosureSEC source: 0001765581-19-000043 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,238 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 00:41 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 351 | $139.50 | $48,964.50 |
DisclosureSEC source: 0001765581-19-000025 · edgardoc.xml · nonDerivative · entry 3 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,709 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 00:41 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 523 | $139.50 | $72,958.50 |
DisclosureSEC source: 0001765581-19-000025 · edgardoc.xml · nonDerivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,060 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:41 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $140.03 | $0.00 |
DisclosureSEC source: 0001765581-19-000025 · edgardoc.xml · derivative · entry 4 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Ordinary Shares · 12,500 shares Expires 2029-02-27 F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 28, 2019, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2019 Filed Mar 5, 2019 00:41 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-19-000025 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,583 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2019, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 125 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2018. Read SEC document |
| August 10, 2018 Filed Aug 13, 2018 23:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,309 | $176.61 | $231,183.41 |
DisclosureSEC source: 0001232524-18-000154 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,458 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $176.61 to $177.061. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. F3 · balance_after: Includes 126 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| March 06, 2018 Filed Mar 7, 2018 21:10 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 594 | $141.47 | $84,030.21 |
DisclosureSEC source: 0001232524-18-000061 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,641 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 352 | $139.63 | $49,148.28 |
DisclosureSEC source: 0001232524-18-000048 · edgardoc.xml · nonDerivative · entry 3 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,235 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 525 | $139.62 | $73,298.14 |
DisclosureSEC source: 0001232524-18-000048 · edgardoc.xml · nonDerivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,587 F3 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 9,000 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000048 · edgardoc.xml · derivative · entry 4 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Ordinary Shares · 9,000 shares Expires 2028-02-29 F4 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000048 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,112 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 127 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 20:59 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,104 | $143.30 | $158,203.20 |
DisclosureSEC source: 0001615763-17-000003 · edgardoc.xml · nonDerivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,385 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document |
| August 14, 2017 Filed Aug 15, 2017 20:59 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 200 | $143.41 | $28,681.20 |
DisclosureSEC source: 0001615763-17-000003 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,489 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · balance_after: Includes 110 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2017. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 529 | $131.97 | $69,814.72 |
DisclosureSEC source: 0001232524-17-000073 · edgardoc.xml · nonDerivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,579 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F3 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.5330 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:39 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 355 | $131.97 | $46,850.95 |
DisclosureSEC source: 0001232524-17-000073 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,108 F1 · kind: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $131.4935 to $131.9800. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,250 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000062 · edgardoc.xml · derivative · entry 2 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Ordinary Shares · 11,250 shares Expires 2027-03-01 F3 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:56 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000062 · edgardoc.xml · nonDerivative · entry 1 Treacy Paul · CIK 0001615763 · SVP, Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,463 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 93 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.